37Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
New Zealand
Neuroscience Intelligence
New Zealand neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #42 of 50 · Data maturity A · Research score 28.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
9Recruiting trials
33Publications
24Institutions
Executive interpretation
New Zealand ranks #42 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC73 recruiting
Pfizer50 recruiting
Celgene20 recruiting
AbbVie20 recruiting
Forest Laboratories20 recruiting
Boehringer Ingelheim10 recruiting
Annexon, Inc.11 recruiting
Living Cell Technologies10 recruiting
BRC Operations Pty. Ltd.10 recruiting
Chelsea Therapeutics10 recruiting
Disease activity
Parkinsons11trials
Stroke3trials
Epilepsy2trials
Multiple Sclerosis2trials
Autism2trials
Alzheimers2trials
Movement Disorders1trials
Depression1trials
Other Neurology1trials
Other Psychiatry1trials
Research institutions
Palmerston North HospitalOpenAlexlinked institution
University of OtagoOpenAlexlinked institution
Auckland City HospitalOpenAlexlinked institution
Nelson Marlborough Institute of TechnologyOpenAlexlinked institution
Victoria University of WellingtonOpenAlexlinked institution
Department of ConservationOpenAlexlinked institution
Capital and Coast District Health BoardOpenAlexlinked institution
Middlemore HospitalOpenAlexlinked institution
Brain Research New ZealandOpenAlexlinked institution
Starship Children's HealthOpenAlexlinked institution
Clinical evidence trail
NCT07777549A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)NOT_YET_RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06961006A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)RECRUITING
NCT06510816A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)ACTIVE_NOT_RECRUITING
NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationRECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT02855476HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's DiseaseRECRUITING
NCT05540522A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or OlderCOMPLETED
NCT05211947A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyTERMINATED
Research evidence trail
PUBMEDEarly Arterial Oxygen Tension Thresholds for Mechanically Ventilated Patients with Non-traumatic Acute Brain Injury: A Bayesian Analysis of Three Large Neurocritical Care Datasets.2026-09-28
PUBMEDPrimary care clinicians' perspectives on migraine management in Aotearoa New Zealand: a qualitative study.2026-09-24
PUBMEDFactors associated with variability in recovery after mild traumatic brain injury among adults referred to outpatient concussion clinics.2026-09-24
PUBMEDDabigatran use and cerebrovascular event risk across body mass index in atrial fibrillation: a real-world nested case-control study.2026-09-07
PUBMEDDevelopment-related gene expression disruption in the human midcingulate cortex in Huntington's disease.2026-08-01
PUBMEDExploration of the genetic neuroinflammatory environment in the human midcingulate cortex in Huntington's disease.2026-06-04
PUBMEDStroke reperfusion in Aotearoa New Zealand: 5-year trends and a comparison of stroke clot retrieval and non-stroke clot retrieval centre presenters.2026-01-01
PUBMEDNeural mechanisms underlying cognitive inflexibility in obsessive-compulsive disorder: a review.2026-01-01
OPENALEXPragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission2023-10-09
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.